Back to News
Market Impact: 0.12
MEDVi QUAD New Formula 2026: Apomorphine Replaces PT-141 in Updated 4-in-1 Compounded ED Treatment
Source: Newswire
Healthcare & BiotechProduct Launches
MEDVi announced QUAD®, a compounded single-dose formulation combining sildenafil, tadalafil, apomorphine, and L-citrulline. The product change may be relevant for prospective patients before they begin a licensed-provider evaluation, but the announcement provides no financial metrics, clinical data, regulatory milestones, or expected commercial impact.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.15
More News
- DeepSeek Drops Enhanced Coding Agent With Aim to Rival Anthropic
- The rise of the 15-foot skeleton—how a viral novelty became a Halloween staple
- ‘Like Kashmir’: How a toxic marble dump yard became a tourist spot in India
- Bolt Graphics powers on its first Zeus GPU
- Swiss firms plan to expand China investments as trade deal deepens ties
- Gaza doctors struggle with bereavement, overwork, trauma amid genocidal war